Document Detail


The question of heart failure in ONTARGET and TRANSCEND: implications for clinical practice.
MedLine Citation:
PMID:  19491621     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In patients with arterial hypertension and/or high cardiovascular risk, including patients with diabetes, chronic ischemic heart disease and kidney disease, the risk of heart failure decreases with blood pressure reduction and the use of drugs that inhibit the renin-angiotensin system (RAS) [angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs)]. The heart failure incidence seen in ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) and Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) is in line with this observation. In ONTARGET, telmisartan and ramipril were equally effective in heart failure prevention and with the same blood pressure reduction. The low event rate, including the low incidence of heart failure in TRANSCEND with the greater use of diuretics in the placebo arm, may help to explain the absence of significant differences between telmisartan and placebo.
Authors:
Jos? R Gonz?lez-Juanatey
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of hypertension. Supplement : official journal of the International Society of Hypertension     Volume:  27     ISSN:  0952-1178     ISO Abbreviation:  J Hypertens Suppl     Publication Date:  2009 Jun 
Date Detail:
Created Date:  2009-06-03     Completed Date:  2009-09-01     Revised Date:  2010-05-18    
Medline Journal Info:
Nlm Unique ID:  8501422     Medline TA:  J Hypertens Suppl     Country:  England    
Other Details:
Languages:  eng     Pagination:  S32-5     Citation Subset:  IM    
Affiliation:
Cardiology Department, Hospital Cl?nico Universitario, Santiago de Compostela, Spain. jose.ramon.gonzalez.juanatey@sergas.es
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antihypertensive Agents / pharmacology,  therapeutic use
Heart Failure / complications,  drug therapy,  physiopathology*
Humans
Receptors, Angiotensin / antagonists & inhibitors
Renin-Angiotensin System / drug effects
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Receptors, Angiotensin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Benefits of the RAS blockade: clinical evidence before the ONTARGET study.
Next Document:  ONTARGET, TRANSCEND, and PRoFESS: new-onset diabetes, atrial fibrillation, and left ventricular hype...